| scholarly article | Q13442814 |
| P50 | author | Reza Dana | Q16206939 |
| P2093 | author name string | Mohammad H Dastjerdi | |
| Sunil K Chauhan | |||
| Andre Okanobo | |||
| Shilpa Kodati | |||
| P2860 | cites work | Focus on molecules: interleukin-1: a master regulator of the corneal response to injury. | Q37401805 |
| Plasticity of T-cell phenotype and function: the T helper type 17 example. | Q37634579 | ||
| A clinical perspective of IL-1β as the gatekeeper of inflammation | Q37869439 | ||
| Interleukin-1beta-induced disruption of barrier function in cultured human corneal epithelial cells | Q39890559 | ||
| Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group | Q41730611 | ||
| Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages | Q41887679 | ||
| The crucial role of macrophages in lymphangiogenesis | Q41945366 | ||
| Interleukin 1 receptor antagonist suppresses allosensitization in corneal transplantation | Q42685066 | ||
| Role of Th17 cells in the immunopathogenesis of dry eye disease | Q42694095 | ||
| Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease | Q43723395 | ||
| Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome | Q44006693 | ||
| Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts | Q44226517 | ||
| Antiinflammatory therapy for dry eye. | Q44763839 | ||
| Inflammation in dry eye. | Q46372528 | ||
| The controlled-environment chamber: a new mouse model of dry eye. | Q46618772 | ||
| LYVE-1-positive macrophages are present in normal murine eyes. | Q50687535 | ||
| Desiccating Stress Induces T Cell-Mediated Sjogren's Syndrome-Like Lacrimal Keratoconjunctivitis | Q61851332 | ||
| Presence of Langerhans cells in the central cornea linked to the development of ocular herpes in mice | Q67503463 | ||
| Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group | Q72472826 | ||
| The role of cytokines in rheumatoid arthritis: inhibition of cytokines in therapeutic trials | Q73939910 | ||
| Interleukin-1 receptor antagonist | Q77118254 | ||
| Role of macrophages in inflammatory lymphangiogenesis: Enhanced production of vascular endothelial growth factor C and D through NF-kappaB activation | Q79704928 | ||
| The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007) | Q80347907 | ||
| CCR5 chemokine receptor mediates recruitment of MHC class II-positive Langerhans cells in the mouse corneal epithelium | Q81575316 | ||
| Exposure to a dry environment induces strain-specific responses in mice | Q94520420 | ||
| Th17 and regulatory T cells in mediating and restraining inflammation | Q27687428 | ||
| Corneal avascularity is due to soluble VEGF receptor-1 | Q28755125 | ||
| Biologic basis for interleukin-1 in disease | Q29619853 | ||
| Mouse IL-1 receptor antagonist isoforms: complementary DNA cloning and protein expression of intracellular isoform and tissue distribution of secreted and intracellular IL-1 receptor antagonist in vivo | Q32067139 | ||
| Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome | Q33592784 | ||
| Characterization of effector T cells in dry eye disease | Q34065949 | ||
| Curcumin protects against hyperosmoticity-induced IL-1beta elevation in human corneal epithelial cell via MAPK pathways | Q34089311 | ||
| Novel characterization of MHC class II-negative population of resident corneal Langerhans cell-type dendritic cells. | Q34116123 | ||
| Ocular complications of topical, peri-ocular, and systemic corticosteroids | Q34120572 | ||
| The corneal stroma is endowed with a significant number of resident dendritic cells | Q34173660 | ||
| The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. | Q34317970 | ||
| Interleukin-1 receptor antagonist | Q34354989 | ||
| Topical omega-3 and omega-6 fatty acids for treatment of dry eye. | Q34749224 | ||
| Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity? | Q34952967 | ||
| Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision | Q34984061 | ||
| On the dynamics of T-cell activation in lymph nodes | Q35675895 | ||
| Impact of dry eye syndrome on vision-related quality of life | Q35741609 | ||
| Tear film and ocular surface tests in animal models of dry eye: uses and limitations | Q35925823 | ||
| IL-17 disrupts corneal barrier following desiccating stress. | Q36676135 | ||
| Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease | Q36776787 | ||
| Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression | Q37071969 | ||
| Topical interleukin-1 receptor antagonist inhibits inflammatory cell infiltration into the cornea | Q37221252 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 63-71 | |
| P577 | publication date | 2012-04-26 | |
| P1433 | published in | American Journal of Ophthalmology | Q4744258 |
| P1476 | title | Efficacy of topical blockade of interleukin-1 in experimental dry eye disease | |
| P478 | volume | 154 |
| Q38886086 | Ageing and ocular surface immunity. |
| Q38207723 | An update on dry eye disease molecular treatment: advances in drug pipelines |
| Q90323769 | Application of autologous serum eye drops after pterygium surgery: a prospective study |
| Q38235721 | Current Approach to Dry Eye Disease. |
| Q35570541 | Cyclosporine ophthalmic emulsions for the treatment of dry eye: a review of the clinical evidence |
| Q27676526 | Design of a superior cytokine antagonist for topical ophthalmic use |
| Q37242107 | Do Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells? |
| Q34647761 | Dry eye as a mucosal autoimmune disease |
| Q37054835 | Dry eye modifies the thermal and menthol responses in rat corneal primary afferent cool cells |
| Q47639135 | Dry eye syndrome: developments and lifitegrast in perspective |
| Q26852044 | Dry eye: an inflammatory ocular disease |
| Q34473772 | Establishing PAX6 as a biomarker to detect early loss of ocular phenotype in human patients with Sjögren's syndrome |
| Q38608263 | From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. |
| Q35058600 | Hevin plays a pivotal role in corneal wound healing. |
| Q36665694 | IL-1β promotes corneal epithelial cell migration by increasing MMP-9 expression through NF-κB- and AP-1-dependent pathways |
| Q36872927 | Inflammatory Response to Lipopolysaccharide on the Ocular Surface in a Murine Dry Eye Model. |
| Q38161374 | Lymphatic vessels: new targets for the treatment of inflammatory diseases |
| Q47442388 | Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation. |
| Q55355486 | MyD88 Deficiency Protects Against Dry Eye–Induced Damage. |
| Q90300781 | Neutralization of Streptolysin S-Dependent and Independent Inflammatory Cytokine IL-1β Activity Reduces Pathology During Early Group A Streptococcal Skin Infection |
| Q35907009 | Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease |
| Q47861500 | Reduction of product-related species during the fermentation and purification of a recombinant IL-1 receptor antagonist at the laboratory and pilot scale |
| Q36986476 | Spdef null mice lack conjunctival goblet cells and provide a model of dry eye. |
| Q42792794 | Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: comparative study with the conventional cyclosporin A emulsion |
| Q47138569 | TRI Microspheres prevent key signs of dry eye disease in a murine, inflammatory model. |
| Q34510429 | The core mechanism of dry eye disease is inflammation |
| Q52768652 | The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases. |
| Q38219053 | The eye: a window of opportunity in rheumatoid arthritis? |
| Q50110517 | Therapeutic inhibitors for the treatment of dry eye syndrome. |
| Q37195776 | Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease. |
| Q34206399 | Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. |
| Q37397203 | What is the value of incorporating tear osmolarity measurement in assessing patient response to therapy in dry eye disease? |
Search more.